Ifx-Hu2.0

Cutaneous Neuroendocrine Carcinoma

TuHURA Biosciences, Inc.vaccinePhase 2/3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 81/ 100

Competitive context

44 Active assets in the Cutaneous Neuroendocrine Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Pembrolizumab Merck Sharp & Dohme LLC	Phase 3	BB
Cyclophosphamide Merck Sharp & Dohme LLC	Phase 2/3	BB
Fludarabine Sotio Biotech Inc.	Phase 2	B
Nivolumab Fred Hutchinson Cancer Center	Phase 2	B
Durvalumab Ariceum Therapeutics GmbH	Phase 2	B

View all 50 →

Same molecule, other indications

Ifx-Hu2.0 is also rated in:

skin carcinomaDormant

CC

Indicative · Phase 1

47 / 100

skin squamous cell carcinomaDormant

CC

Indicative · Phase 1

44 / 100

cutaneous melanomaDormant

CC

Indicative · Early Phase 1

43 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.